The Radboudumc receives a grant of 2.5 million euros for research into the rejection of transplant organs. With this ERC Grant from the European Union, Willem Mulder will research new nanotechnology to prevent organ rejection in patients who have received a transplanted organ.
Taking control of innate immunity to achieve organ transplant acceptance
Together with his colleagues at Tu/e Willem Mulder of Internal Medicine will explore novel nanotechnology to prevent organ rejection in patients who have received a transplanted organ. Organ rejection is caused by our immune system, which fights any foreign element that is introduced into our body. While there are effective drugs on the market to suppress this reaction, chronic immunosuppression comes at a tremendous price. The drugs cause serious adverse effects, including cancer, and long-term rejection remains a serious problem.
Rejection is mediated by innate immune system activation, which together with the adaptive immune system is responsible for our body’s defense against infections and other diseases. Recently, it has become clear that this innate system, just as our adaptive system, harbors a memory function, opening new avenues for treating illnesses like cancer.
It is this innate system that Mulder and his colleagues also want to harness to increase our body’s tolerance to transplanted organs. “The current strategy in organ transplantation is to suppress an already activated immune system, seriously compromising a patient’s ability to fight off disease. Our focus is on preventing immune system activation using highly innovative nanotechnology that integrates RNA or immunoregulatory proteins”, says Mulder.
While focusing on kidney transplant patients, the research can have wide-ranging benefits for other patients. “Similar innate immunity-focused disease management strategies can be developed for other conditions that are characterized by an exacerbated immune response. Think of COVID-19, autoimmune and cardiovascular diseases.”
The European Research Council was set up by the European Union in 2007 and is the most important European funding organization for groundbreaking research. Advanced ERC grants are aimed at well-established top researchers, who have a recent high-level research track-record and profile which identifies them as leaders in their respective field. Grants can amount to 2.5 million euros per grant (or 3.5 million in exceptional cases).
Related news items
ZonMw Open Competition Grant for Annemiek van Spriel and Piet Gros15 June 2021
Annemiek van Spriel, theme cancer development and immune defense, together with Piet Gros, Dept. of Chemistry, Utrecht University obtained a ZonMw Open Competition Grant to investigate IL-6 receptor structure and signalling in tumor cells.read more
Human microbiome could shed light on higher morbidity rate in minoritized populations The link between environmental inequities and disease may lie in the gut15 June 2021
A study published in PNAS is the first to explicitly address the gut microbiome as a pathway to understanding how environmental inequities could lead to health disparities.read more
New ultra-high field MRI system available for Radboudumc and Radboud University10 June 2021
Recently, the Hahn institute in Essen has received a new heart: a 20-ton ultra-high-field MRI scanner from Siemens Healthcare with a magnetic field strength of 7 Tesla. The new CE-approved scanner is ready for business, and projects on body and brain imaging are starting up.read more
On the prevalence of cerebral amyloid angiopathy a systematic review and meta-analysis10 June 2021
Published in ‘Alzheimers and Dementia’, researchers at Radboudumc performed a systematic review and meta-analysis on the prevalence of Cerebral Amyloid Angiopathy. They scrutinized and analyzed 170 publications, comprising publications using either a neuroimaging or a neuropathological approach.read more
Retina-on-chip modeling and treating eye diseases in a dish10 June 2021
Alex Garanto, together with Anneke den Hollander and Andries van der Meer (UTwente) have received 1,17M€ to develop a retina-on-chip model to improve our understanding in eye diseases and to develop treatments against them.read more
A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses8 June 2021
Jeroen Creemers and Johannes Textor published in the Journal for ImmunoTherapy of Cancer that a tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery.read more